Ionic Capital Management’s Humacyte HUMA Stock Holding History

Ionic Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,499	Closed	-$127K	–	348
2020 Q4	$127K	Buy	+12,499	New	+$124K	0.02%	212

Other funds holding HUMA

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

WRBC

W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Ionic Capital Management's HUMA Position: Q1 2021 in Review

Ionic Capital Management sold out of Humacyte (HUMA) in Q1 2021, closing a stake of 12,499 shares — an estimated $127K sold.

Ionic Capital Management first reported a position in HUMA in Q4 2020 and held it in 1 quarter. The position peaked at $127K in Q4 2020. 23 funds tracked by Wall St. Rank hold HUMA as of Q1 2021.

Ionic Capital Management reported no remaining Humacyte position as of Q1 2021 after selling out during the quarter.
Ionic Capital Management sold 12,499 Humacyte shares in Q1 2021, an estimated $127K.
Ionic Capital Management first reported a position in Humacyte in Q4 2020 and held it in 1 quarter.
Ionic Capital Management's Humacyte position peaked at $127K in Q4 2020.
23 funds tracked by Wall St. Rank held Humacyte as of Q1 2021.

Based on Ionic Capital Management's 13F filing for Q1 2021, filed 17 May 2021.